Identifying new targets for monoclonal antibodies in immunotherapy
Nuovi Bersagli Per lo Sviluppo di Anticorpi Monoclonali Per Immunoterapia - (Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)
This study is testing new targets for cancer treatment by looking at immune cells in healthy blood donors to see if certain antibodies can help improve immunotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 600 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Checkmab S.r.l. Industry-sponsored |
| Locations | 1 site (Milan) |
| Trial ID | NCT06842407 on ClinicalTrials.gov |
What this trial studies
This project aims to preclinically validate new molecular targets associated with intratumoral T regulatory cells. It will also involve selecting monoclonal antibodies that have therapeutic potential specific to these targets. The study focuses on healthy blood donors who meet specific eligibility criteria, allowing for the exploration of immune responses relevant to cancer treatment. By identifying these targets, the research could pave the way for innovative immunotherapeutic strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy adults aged 18 years or older who are eligible to donate blood.
Not a fit: Patients who are under 18 years old or have infectious diseases such as HIV, HCV, or HBV will not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective immunotherapies for cancer patients.
How similar studies have performed: While this approach is innovative, similar studies targeting T regulatory cells have shown promise in the past, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * blood donors * age of 18 years or more * able to sign informed consent Exclusion Criteria: * age below 18 years * Positive for HIV, HCV, HBV * not suitable for blood donation * not able to understand or sign informed consent
Where this trial is running
Milan
- S.C. Medicina Trasfusionale - Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico — Milan, Italy (Recruiting)
Study contacts
- Study coordinator: Renata M Grifantini, PhD
- Email: renata.grifantini@checkmab.eu
- Phone: 0039 00660220
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.